A Phase 2 Study of PCI-27483, a Factor VIIa Inhibitor in Combination with Gemcitabine for Advanced Pancreatic Cancer
Conclusions: Targeted inhibition of the coagulation cascade was achieved by administering PCI-27483. PCI-27483 –gemcitabine was well tolerated, but superiority to single agent gemcitabine was not demonstrated.Oncology 2019;96:1 –6
Source: Oncology - Category: Cancer & Oncology Source Type: research
More News: Bleeding | Cancer | Cancer & Oncology | Pancreas | Pancreatic Cancer | Study | Thrombosis